Thursday, 15 October 2026European Markets

ASR NEDERLAND Stock Was Up By 12.03% Today

Loading stream...

(VIANEWS) - The Market ended the session with ASR NEDERLAND (ASRNL.AS) jumping 12.03% to €41.92 on Thursday, following the last session's downward trend. AEX-Index jumped 0.4% to €765.04, following the last session's upward trend on what was a somewhat positive trend exchanging session today.

ASR NEDERLAND's last close was €37.42, 18.35% under its 52-week high of €45.83.

About ASR NEDERLAND

ASR Nederland N.V. provides insurance, pensions, and mortgages products for consumers, self-employed persons, and companies. It operates through five segments: Non-Life, Life, Asset Management, Distribution and Services, and Holding and Other. The company offers health, life, pension, funeral expense, and occupational disability insurance products; and non-life insurance products, including road traffic, fire, third-party liability and legal assistance insurance. It also provides financial intermediary services; and develops real estate properties, as well as operates as an asset manager for third parties. ASR Nederland N.V. offers its products under the Loyalis, Ditzo, Europeesche Verzekeringen, a.s.r. asset management, Ardanta, and a.s.r. brand names. The company was formerly known as Fortis Verzekeringen Nederland N.V. and changed its name to ASR Nederland N.V. in October 2008. ASR Nederland N.V. was founded in 1720 and is headquartered in Utrecht, the Netherlands.

Earnings Per Share

As for profitability, ASR NEDERLAND has a trailing twelve months EPS of €17.72.

PE Ratio

ASR NEDERLAND has a trailing twelve months price to earnings ratio of 2.37. Meaning, the purchaser of the share is investing €2.37 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 39.77%.

More news about ASR NEDERLAND (ASRNL.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
ASR NEDERLAND Stock Was Up By 12.03% Today | ViaNews EU